0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

J-L. Harousseau Tipifarnib in hematologic malignancies

Authors

Farnesyltranferase inhibitors (FTI) are signal transduction inhibitors that block farnesylation of a number of proteins including Ras that are involved in key cellular functions (proliferation,survival and differentiation).1,2 Tipifarnib is a potent inhibitor of farnesyltransferase that is orally bioavailable. Tipifarnib was initially developed with the goal of targeting Ras in cancers with a high incidence of Ras mutations. However, after failure of large clinical trials in solid tumors (pancreas, colon) further development was mainly focused on hematologic malignancies

Supporting Agencies

How to Cite

Harousseau, J. (2009). J-L. Harousseau Tipifarnib in hematologic malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.756